About Jefferson Innovation


Name: Jefferson Innovation

925 Chestnut Street
Suite 110
Philadelphia, PA 19107

Contact Number(s):

We Are Jefferson

Reimagine is our commitment to raising the resources it takes to change the world in multiple, meaningful ways. We’re going to change the future for Philadelphia and beyond:

  • People Leading Optimistic Revolutions
  • Spaces that Heal and Inspire
  • Communities United for Health Equity
  • Discoveries that Improve Lives

Learn More ...

Current Investment Opportunities


There are 52,000 brain tumor resections in the US annually, 25,000 of which are glioblastomas. With a median length of survival around 15 months, treatment options for glioblastoma fall far short of what oncologists would like to offer their patients.

Paul Stauffer, TJU founding scientist of Brachythermix, was involved in a clinical study that showed that combining heat with radiation therapy in tumor cavities after tumor removal doubled the 2 year survival rate in glioblastoma patients; unfortunately employing this procedure involved a roomful of complicated and delicate machinery that was not suitable for commercialization.

To simplify this treatment methodology and make it more accessible, Dr. Stauffer developed a simple balloon based device that allows for simultaneous heat and radiation therapy in tumor cavities after resection. International patent application number: PCT/US2017/025523

While the initial market is GBM, the technology has potential applications in many other resectable tumor sites so there are significant additional sales of devices anticipated for treatment of other cancers.

BrachyThermix was formed in 2018. The Company is currently seeking to raise $3 million to complete prototype development and clinical validation and submit 510(k) data to the FDA.

929-256-2950  |  http://brachythermix.com

Capillary Biomedical

Insulin pump therapy is the gold standard of intensive diabetes care management. There are 1.2 M current insulin pump users which on average pay $1,200 per year for pump therapy consumables. An additional 2.4 M people with diabetes who currently inject insulin multiple times a day are candidates for pump therapy. However, research shows that improving the body-worn infusion set and its cannula through which the drug is dispensed into tissue under the skin is the key barrier to improving the reliability and convenience of insulin pump therapy. In clinical trials of extended use infusion sets, 65% fail by the 7th Day of use. These failed infusion sets create life-disrupting issues for people with diabetes.

Capillary Biomedical aims to simplify insulin delivery and reduce the burden of diabetes on patients and the healthcare system.  The Company’s first product, the SteadiSet™ infusion set with SteadiFlow™ technology, is designed to improve the reliability and comfort of insulin delivery via a kink-proof, flexible, multiport cannula. Simple one-handed insertion and advanced adhesive complete the user-friendly design.  By addressing the weak link of insulin pump therapy, the SteadiSet will enable more people with diabetes to reliably achieve improved blood glucose control.  Located in Irvine, California the company was spun-out of the Artificial Pancreas Center, Sidney Kimmel Medical College, Thomas Jefferson University.

The Company has completed development and preclinical testing and will conduct clinical trials in 2019 to support 510(k) US regulatory clearance and CE Marking during the second half of 2019.   The company plans to raise $20 Million in a Series A preferred equity financing round to complete the clinical work, scale-up production and commercialize the product in 2020.

8 Faraday, Suite B, Irvine CA 92618  |  833-277-2461  |  http://capillarybio.com

NuView Life Sciences

Currently in the US there are 1,800,000 tissue biopsies performed annually because of high PSA test levels. Ultimately, seventy percent (1,260,000) of these prostate tissue biopsies are negative. Nonetheless of its diagnostic importance, each of these biopsies is invasive – and have the very real potential of causing serious complications such as pain, infections, bleeding and even erectile dysfunction in patients. These unnecessary biopsies also cause a huge financial burden for healthcare payers and a loss of productivity for MD to focus on patients who need care. Using technology developed at Thomas Jefferson University, NuView Diagnostics has developed a first-of-kind precision in vitro diagnostic test (liquid biopsy) that targets cancer cells in voided urine with an initial focus on prostate cancer. NuView’s optical imaging test confirms the presence of cancer cells by binding to the cancer cell surface overexpressing the VPAC/VIP receptors. NV-VPAC1 in vitro test is simple, accurate, cost-effective and non-invasive. This diagnostic test will provide high predictive value, and eliminate unnecessary procedures therefore significantly reducing healthcare costs for payers or purchasers of medical services. This diagnostic test offers high value for patients, service providers and purchasers of healthcare services. The company has recently launched patient validation studies in multiple sites and anticipates market entry in 2021.

1389 Center Drive, Suite 250, Park City UT 84098  |  888-902-7779  |  http://nuviewinfo.com

RTM Vital Signs

RTM develops real-time vital sign monitoring devices based on proprietary technology to improve clinical care and reduce costs in two critical areas of healthcare concern: cardiovascular disease and opioid misuse.  

Cardiovascular disease is the leading cause of death globally as well as the most significant contributor to US healthcare costs ($1 in every $6), including the high cost of unnecessary emergency room visits. Yet at present, there is no technology commercially available that can report the physical signs of an impending cardiac event in time for appropriate preventive intervention. Using technology developed at Thomas Jefferson University, RTM Vital Signs, LC is developing a miniature, long-term monitoring system, implantable under local anesthesia in an outpatient procedure that accurately and continuously measures the arterial blood pressure waveform, the electrocardiogram, respiratory rate, tidal volume, hemoglobin oxygen saturation, and sounds of the heart, lungs and upper airway in out-of-hospital patients with high-risk cardiovascular disease. Sensor data from the device will feed predictive algorithms to improve diagnostics and medication dosing related to hypertension and other cardiac issues, ultimately leading to prediction and prevention of adverse cardiac events. Real-time data can also be transmitted to a smart phone or central monitoring station to timely alert patient, caregiver, and/or emergency care. Recent data captured by the device could also be downloaded on-demand by EMR personnel, physicians or clinicians as needed. Improved monitoring, diagnosis and management of cardiac care can save lives, lower costs and expand knowledge. No active patient involvement or reporting is needed. An initial prototype of the device has been bench tested. The implantation method and a 4-week in-vivo (canine) test with a mock-up was also completed in early 2018 with positive results. A fully -functional, actual-scale sensor that continuously monitors the arterial blood pressure waveform is now being manufactured and animal testing for the device is expected to begin about April 2019.

Every 10 minutes someone in the US dies of an opioid overdose. The cost of the opioid crisis exceeds $78B/yr.  Overdose victims die in hospitals, at home, with others present or alone. The Joint Commission has recommended that anyone taking post-operative opioids be continuously monitored.  Opioid deaths are preventable. A critical need exists for a simple, wearable device that can accurately predict an impending opioid overdose and automatically alert the patient, caregiver/ER in time for life-saving intervention.  RTM's wearable acoustic sensor will accurately measure the respiratory rate, tidal volume, oxygen saturation, body position and activity level of ambulatory or in-hospital patients for the onset of hypoventilation which signals an opioid overdose or respiratory distress.  The device will send timely alerts/alarms before the individual reaches a state of permanent adverse health impact or death.  A prototype system will be tested in human trials at Thomas Jefferson University in early 2019 to optimize our sensor design and machine learning diagnostic algorithms.   

RTM currently seeks to raise $ 3 million over the next 12 months to fund further development of the two projects. 

439 Dreshertown Road, Fort Washington PA 19034  |  215-643-1286 https://rtmvitalsigns.com